Product information and disease descriptionPlace of product in therapyDisease description
Epidemiology
12 evidence topics · 9 sources
Tovecimig (CTX-009)
Second-line advanced biliary tract cancer
- Manufacturer
- Compass Therapeutics
- Regulatory submission
- BLA planned for the fourth quarter of 2026
- Launch
- Anticipated in 2027
- Last updated